Here we tested if targeting both BAFF and ICOSL has superior efficacy than single target inhibition in the mouse arthritis and lupus models. We also generated AMG 570, an ICOSL and BAFF bispecific inhibitory molecule, for potential treatment of autoimmune diseases such as SLE.

AMG 570AMG 570是一款潜在“first-in-class”抗体多肽偶联药物，能够同时抑制刺激T细胞的ICOSL信号通路和刺激B细胞的BAFF信号通路，从而更有效地治疗多种自身免疫性疾病。

2021年4月13日 · baff(b细胞激活因子)又称blys（b淋巴细胞刺激因子），可通过与b细胞上表达的baff受体(baffr)结合支持b细胞存活。 BAFF是一种II型跨膜蛋白，主要由单核细胞和树突状细胞表达。

2023年5月7日 · Aberrant activation of B-cell activating factor (BAFF) and inducible T-cell costimulator ligand (ICOSL) pathways underlies multiple autoimmune diseases. Rozibafusp alfa is a first-in-class bispecific antibody-peptide fusion designed to inhibit BAFF and ICOSL.

2024年7月18日 · Rozibafusp alfa (AMG-570) is a first-in-class bispecific antibody-peptide conjugate that inhibits BAFF and inducible costimulator ligand (ICOSL). The ICOS/ICOSL costimulatory pathway is important for T-cell activation, migration, differentiation, and antibody production, mediated by interactions between follicular helper T-cells and B-cells.

Rozibafusp alfa (AMG 570) is a first-in-class bispecific IgG2-peptide fusion designed to inhibit inducible T-cell costimulator ligand (ICOSL) and B-cell activating factor (BAFF). The pharmacokinetics (PK) and pharmacodynamics (PD) of rozibafusp alfa were investigated in two randomized, placebo-contr …

Objective: To assess the safety and biological activity of rozibafusp alfa, a first-in-class bispecific antibody-peptide conjugate targeting inducible costimulator ligand (ICOSL) and B cell activating factor (BAFF), in patients with rheumatoid arthritis (RA).

2023年5月7日 · Rozibafusp alfa是一种新型双特异性抑制剂，可以同时抑制B淋巴细胞激活因子（BAFF）和可诱导T细胞共刺激因子配体（ICOSL），被认为是治疗自身免疫性疾病的潜在药物。

icos主要在活化的t细胞上表达，其配体icosl主要在b细胞和抗原呈递细胞上表达。 通过与ICOSL结合发挥作用，ICOS可诱导细胞增殖、存活和分化，并调节多种T细胞功能。

AMG 570 is a bispecific molecule targeting T cell and B cell activity through inhibition of the inducible costimulator ligand (ICOSL) and the B cell activating factor (BAFF). We hypothesize that targeting both ICOSL and BAFF will be more effective than single target inhibition in SLE and other autoimmune diseases.